Table 1. Patient demographics and baseline disease characteristics.
| Characteristic | No ZOL ( n =59) | ZOL ( n =60) |
|---|---|---|
| Mean age, years (range) | 49.1 (32–69) | 50 (30–68) |
| Race, n (%) | ||
| Caucasian | 45 (76.3) | 39 (65) |
| African American | 11 (18.6) | 20 (33) |
| Menopausal status, n (%) | ||
| Premenopausal | 33 (55.9) | 31 (51.7) |
| Postmenopausal | 26 (44.1) | 29 (48.3) |
| Pathology, n (%) | ||
| Ductal carcinoma | 49 (83.1) | 47 (78.3) |
| Lobular carcinoma | 7 (11.8) | 7 (11.7) |
| Other | 3 (5.1) | 6 (10) |
| Mean tumour size, cm (s.d.) | 3.56 (2.41) | 3.81 (2.03) |
| Lymph-node positive, n (%) | 33 (55.9) | 38 (63.3) |
| Grade, n (%) | ||
| I | 2 (3.4) | 7 (11.7) |
| II | 28 (47.5) | 20 (33.3) |
| III | 29 (49.2) | 33 (55) |
| Receptor status, n (%) | ||
| ER+/HER2+ | 5 (8.5) | 6 (10) |
| ER+/HER2− | 29 (49.2) | 26 (43.3) |
| ER−/HER2+ | 5 (8.5) | 7 (11.7) |
| ER−/HER2− | 19 (32.2) | 21 (35) |
| Unknown | 1 (1.7) | — |
Abbreviations: ER=oestrogen receptor; HER2=human epidermal growth factor receptor-2; s.d.=standard deviation; ZOL=zoledronic acid.
Some of these patient data were previously published (Aft et al, 2010).